Overall survival at five years in patients with advanced ovarian carcinoma

Authors

  • Zeila Omar Robert Hospital Oncológico Docente Conrado Benítez https://orcid.org/0000-0001-9285-6997
  • Isora Sánchez Veranes
  • Yorgan Gómez Neyra
  • Víctor Juan Alfonso Querts
  • Laura Elena Hormigó Polo

Abstract

Introduction: Epithelial ovarian tumors are the most frequent sort affecting this organ, and a large number of them are diagnosed at advanced stages.

Objective: Determine overall survival at five years according to tumor stage, histological type and therapeutic schemes, in patients with stage III and IV ovarian cancer treated at Conrado Benítez Oncological Hospital.

Methods: A descriptive cross-sectional retrospective study was conducted of 62 advanced ovarian carcinoma patients treated at Conrado Benítez Oncological Hospital in the period 2012-2014. Follow-up data were collected until 31 December 2019. The Kaplan-Meier method was applied.

Results: Mean age was 60 years. The prevailing age group was 50-59 years with 19 patients (30.6%). The most common histological type was serous cystadenocarcinoma with 29 patients (46.8%), and most patients were treated with interval surgery (30 patients, 48.4%). Overall survival at five years was 48.4%, and the patients with the highest survival rate were the ones with mucinous carcinoma (100%), at stage IIIA (78.6%), treated with neoadjuvants (73.3%), and undergoing optimal surgery (73.3%).

Conclusions: Overall survival at five years was low, inversely proportional to the clinical stage and higher in patients treated with optimal surgery receiving neoadjuvants.

Key words: ovarian carcinoma, advanced stage, survival.

Downloads

Download data is not yet available.

Author Biography

Zeila Omar Robert, Hospital Oncológico Docente Conrado Benítez

Vicedirector Docente

References

1. Organización Mundial de la Salud. Cáncer. Ginebra: OMS; 2018 [citado 05/02/2019]. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/cancer

2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68(6):394–424. https://doi.org/10.3322/caac.21492 PMID:30207593

3. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F (2019). Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 144(8):1941–1953. https://doi.org/10.1002/ijc.31937 PMID:30350310

4. Cuba. Ministerio de Salud Pública; Dirección de Registros Médicos y Estadísticas de Salud. Anuario estadístico de salud 2015. La Habana: MINSAP; 2016 [citado 05/02/2019]. Disponible en: http://files.sld.cu/dne/files/2016/04/Anuario_2015_electronico-1.pdf

5. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2018). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/25-Ovary-fact-sheet.pdf , accessed [21 Jul 2020].

6. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30.

7. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review, 1975-2016. Bethesda: National Cancer Institute; 2018 [citado 05/02/2019]. Disponible en: https://seer.cancer.gov/csr/1975_2016/

8. Rebasa P. Conceptos básicos del análisis de supervivencia. Cir Esp (Internet). 2015(citado 2020 Jul 20);78(4):222-30. Disponible en: http://dx.doi.org/10.1016/S0009-739X(05)70923-4

9. Fukumoto, T.; Park, P.H.; Wu, S.; Fatkhutdinov, N.; Karakashev, S.; Nacarelli, T.; Kossenkov, A.V.; Speicher, D.W.; Jean, S.; Zhang, L. Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Cell Rep. 2018, 22, 3393–3400

10. Wentzensen, N., Poole, E. M., Trabert, B., White, E., Arslan, A. A., Patel, A. V. et al. Ovarian cancer risk factors by histologic subtype: an analysis from the Ovarian Cancer Cohort Consortium. J Clin Oncol 2016; 34: 2888–2898.

11. González M, Barrera CA, Castillo JS. Cáncer epitelial avanzado de ovario en un grupo de pacientes colombianas. Rev Colomb Cancerol 2013;17(4):142-148

12. Rondón M ,Reyna E, Mejía J, Reyna N, Torres D, Fernández A. Factores pronósticos para la sobrevida de pacientes con cáncer de ovario estadio IV. INSPILIP 2018;2 (1): 20-24.

13. Sastre JF, Carballo JJ, Lor MD, de la Iglesia B. Cáncer de ovario. Rev Clín Med Fam [Internet]. 2007;2(2):86-87. Disponible en: https://www.redalyc.org/articulo.oa?id=169618261009

14. Cabrera R, Juárez A, Gallegos R, Álvarez A, López N, Sánchez M. Validación de un instrumento para detectar síntomas indicativos de cáncer de ovario en Querétaro, México. RECIEN 2016;11:40-43. Disponible en:https://rua.ua.es/dspace/bitstream/10045/57444/1/RECIEN_11_02.pdf

15. Mora E, Gutiérrez E. Características de las pacientes con cáncer de ovario en el Hospital de San José, Bogotá D.C., 2009-2013. Repert Med Cir. 2016;25(1):15–21; Disponible en: http://www.elsevier.es/es-revista-repertorio-medicina-cirugia-263-pdf-S0121737216000078

16. López Figueras, AI. Epidemiología descriptiva del cáncer de ovario en la comunidad de Madrid. Análisis de supervivencia. Universidad Complutense de Madrid. Madrid 2010.

17. Kurman RJ, Carcangiu ML, Harrington CS. WHO Classification of Tumours of Female Reproductive Organs, 4th Edition. WHO/IARC Classification of Tumours. Vol.6. Lyon: IARC Publicatons;2014. Disponible en: https://www.iarc.fr/news-events/iarc-publications-who-classificaton-of-tumours-of-female-reproductive-organs-fourth-edition/

18. McCluggage WG, Judge MJ, Clarke BA. Data set for reporting of ovary, fallopian tuve and primary peritoneal carcinoma: recommendations from the international Collaboration on Cancer Reporting (ICCR). Mod Pathol 2015;28:1101-1122. Disponible en: https://www.ncbi.nim.nih.gov/pubmed/26089092.

19. Massad LS, Gao F, Haggemann I, Powell M. Clinical outcomes among womwn with mucinous adenocarcinoma of the ovary. Gynecol Obstet Invest 2016;81:411-415. Disponible en: https://www.ncbi.nim.nih.gov/pubmed/26583769.

20. National Comprehensive Cancer Network. Head and Neck Cancer (Version1.2020). http://www.nccn.org/professionals/physician_gls/pdf/ovarian_cancer.pdf. Accessed October 10, 2020.

21. García YG, Juan AD, Mendiola C. Phase II randomized trial of neoadyuvant chemotherapy with or without bevacizumab in advanced epitelial ovarian cáncer (EOC) (GEICP 1205/NOVA TRIAL) J Clin Oncol 2017;35:Abstract 5508. Disponible en: https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15 suppl.5508

22. van Meurs HS, Tajik P, Hof MH. Which patients benefit most from primary surgery or neoadyuvan chemotherapy in stage IIIC or IV ovarian cáncer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomized trial. Eur J Cancer 2013;49:3191-3201. Disponible en: https://www.ncbi.nim.nih.gov/pubmed/23850170.

23. Gadducci A, Cosio S, Zizioli V. Patterns of recurrence and clinical otcome of patients with stage IIIC to stage IV epitelial ovarian cáncer in complete response after primary debulking surgery plus chemotherapy or neoadyuvant chemotherapy following by interval debulking surgery: an Italian Multicenter Retrospective Study. Int J Gynecol Cancer 2017;27:28-36. Disponible en : https://www.ncbi.nim.nih.gov/pubmed/27870700

24. Mueller JJ, Zhou QC, Iasonos A. Neoadyuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cáncer at a comprehensive cáncer center. Gynecol Oncol 2016;140:436-442. Disponible en: https://www.ncbi.nim.nih.gov/pubmed/26777991.

25. Chiva L, Lapuente F, Castellanos T. What should we expect after a complete cytorreduction at the time of interval of primary debulking surgery in advanced ovarian cáncer? Ann Surg Oncol 2016;23:1666-1673. Disponible en: https://www.ncbi.nim.nih.gov/pubmed/26714955

26. Coleridge SL, Bryant A, Lyons TJ, Goodall RJ, Kehoe S, Morrison J. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. 2019;31(10):CD005343. Disponible en: https://www.ncbi.nim.nih.gov/pubmed/31684686.

27. Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol. 2018;19(12):1680-1687. Disponible en: https://www.ncbi.nim.nih.gov/pubmed/30413383.

Published

2021-06-02

How to Cite

1.
Omar Robert Z, Sánchez Veranes I, Gómez Neyra Y, Alfonso Querts VJ, Hormigó Polo LE. Overall survival at five years in patients with advanced ovarian carcinoma. Rev Cub Oncol [Internet]. 2021 Jun. 2 [cited 2025 Jul. 1];19(1). Available from: https://revoncologia.sld.cu/index.php/onc/article/view/72

Issue

Section

Artículos Originales